Heather Miller

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: RHEUMATOLOGY. 2021;60(5):2217-2222
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
Miller H; Wallman JK; Petersson IF; Saevarsdottir S; Soderlng J; Ernestam S; Askling J; van Vollenhoven R; Neovius M
Article: ARTHRITIS CARE AND RESEARCH. 2016;68(12):1758-1766
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial
Eriksson JK; Wallman JK; Miller H; Petersson IF; Ernestam S; Vivar N; van Vollenhoven RF; Neovius M
Article: RHEUMATOLOGY. 2016;55(4):729-734
Does disease activity at start of biologic therapy influence work-loss in RA patients?
Olofsson T; Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Petersson IF; Askling J; Neovius M
Article: RHEUMATOLOGY. 2015;54(8):1472-1477
Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Askling J; Neovius M
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(Suppl 3):a558-A559
FRI0543 Is baseline disease activity associated with 1-year health care costs & productivity losses after biologic treatment start in patients with ra?
Johansson K; Eriksson JK; Miller H; van Vollenhoven RF; Askling J; Neovius M

Alla övriga publikationer

Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:315-316
MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE
Miller H; Wallman JK; Petersson I; Saevarsdottir S; Soderling J; Ernestam S; Askling J; van Vollenhoven R; Neovius M
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:456
DOES DISEASE ACTIVITY AT START OF BIOLOGIC THERAPY INFLUENCE PRODUCTIVITY LOSSES IN PATIENTS WITH RA?
Johansson K; Olofsson T; Eriksson J; van Vollenhoven R; Miller H; Petersson I; Askling J; Neovius M
Conference publication: VALUE IN HEALTH. 2014;17(3):A55-A56
UTILIZING NORDIC REGISTRIES TO SUPPORT HEALTH ECONOMICS RESEARCH IN RHEUMATIC DISEASES
Miller H
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2014;66:S1104-S1105
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial.
Eriksson JK; Miller H; Karlsson JA; Petersson IF; Ernestam S; Geborek P; van Vollenhoven RF; Neovius M
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:60
Utilization of Nordic registries to support health economics research in rheumatic diseases
Miller H
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:2-3
Does disease activity at start of biologic therapy influence productivity losses in patients with RA?
Johansson K; Olofsson T; Eriksson J; van Vollenhoven R; Miller H; Peterson I; Askling J; Neovius M
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2013;72:558-559
IS BASELINE DISEASE ACTIVITY ASSOCIATED WITH 1-YEAR HEALTH CARE COSTS & PRODUCTIVITY LOSSES AFTER BIOLOGIC TREATMENT START IN PATIENTS WITH RA?
Johansson K; Eriksson JK; Miller H; van Vollenhoven RF; Askling J; Neovius M

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI